PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2018
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a; Interferon beta-1b
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2018 Planned End Date changed from 30 Dec 2018 to 30 Mar 2020.
- 19 Jul 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Mar 2020.